Manila Times Business
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilutionRemaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies”) (Nasdaq: ADPT
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Over 300 non-resident Filipinos, govt, civic leaders gather for diaspora summit
Just now
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
Just now
Doing Good Index 2026: Asia’s US$753 Billion Philanthropic Potential Remains Unrealized
Just now
Quest Global Launches Neprion to Accelerate AI Smart Wearables Launch Readiness
Just now